Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?

IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pharmacology & Therapeutics Pub Date : 2023-11-01 DOI:10.1016/j.pharmthera.2023.108549
Simon Kloock , Christian G. Ziegler , Ulrich Dischinger
{"title":"Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?","authors":"Simon Kloock ,&nbsp;Christian G. Ziegler ,&nbsp;Ulrich Dischinger","doi":"10.1016/j.pharmthera.2023.108549","DOIUrl":null,"url":null,"abstract":"<div><p>Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease, heart failure and non-alcoholic liver disease are a major health and economic burden with steadily increasing numbers worldwide. The need for effective pharmacological treatment options is strong, but, until recently, only few drugs have proven sufficient efficacy and safety. This article provides a comprehensive overview of obesity and its comorbidities, with a special focus on organ-specific pathomechanisms. Bariatric surgery as the so far most-effective therapeutic strategy, current pharmacological treatment options and future treatment strategies will be discussed. An increasing knowledge about the gut-brain axis and especially the identification and physiology of incretins unfolds a high number of potential drug candidates with impressive weight-reducing potential. Future multi-modal therapeutic concepts in obesity treatment may surpass the effectivity of bariatric surgery not only with regard to weight loss, but also to associated comorbidities.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":"251 ","pages":"Article 108549"},"PeriodicalIF":12.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163725823002139/pdfft?md5=3db00c13c3ab618b50ce8d8e26a26802&pid=1-s2.0-S0163725823002139-main.pdf","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0163725823002139","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2

Abstract

Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease, heart failure and non-alcoholic liver disease are a major health and economic burden with steadily increasing numbers worldwide. The need for effective pharmacological treatment options is strong, but, until recently, only few drugs have proven sufficient efficacy and safety. This article provides a comprehensive overview of obesity and its comorbidities, with a special focus on organ-specific pathomechanisms. Bariatric surgery as the so far most-effective therapeutic strategy, current pharmacological treatment options and future treatment strategies will be discussed. An increasing knowledge about the gut-brain axis and especially the identification and physiology of incretins unfolds a high number of potential drug candidates with impressive weight-reducing potential. Future multi-modal therapeutic concepts in obesity treatment may surpass the effectivity of bariatric surgery not only with regard to weight loss, but also to associated comorbidities.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肥胖及其合并症,目前的治疗选择和未来前景:挑战减肥手术?
肥胖及其合并症,包括2型糖尿病、心血管疾病、心力衰竭和非酒精性肝病,是一个主要的健康和经济负担,全球范围内的肥胖人数稳步增加。对有效药物治疗方案的需求很大,但直到最近,只有少数药物被证明具有足够的疗效和安全性。本文对肥胖及其合并症进行了全面的综述,特别关注器官特异性的病理机制。减肥手术是迄今为止最有效的治疗策略,目前的药物治疗选择和未来的治疗策略将进行讨论。对肠脑轴的了解越来越多,尤其是肠促胰岛素的识别和生理学,揭示了大量具有惊人减肥潜力的潜在候选药物。未来肥胖治疗的多模式治疗概念可能会超过减肥手术的有效性,不仅在减肥方面,而且在相关的合并症方面。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
23.00
自引率
0.70%
发文量
222
审稿时长
90 days
期刊介绍: Pharmacology & Therapeutics, in its 20th year, delivers lucid, critical, and authoritative reviews on current pharmacological topics.Articles, commissioned by the editor, follow specific author instructions.This journal maintains its scientific excellence and ranks among the top 10 most cited journals in pharmacology.
期刊最新文献
Pro-resolving lipid mediators and therapeutic innovations in resolution of inflammation. The pharmacodynamic and pharmacological mechanisms underlying nanovesicles of natural products: Developments and challenges. Exploring the landscape of post-translational modification in drug discovery. New drug discovery and development from natural products: Advances and strategies. Neurobiology of cancer: Adrenergic signaling and drug repurposing
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1